<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906619</url>
  </required_header>
  <id_info>
    <org_study_id>EA2_009_10</org_study_id>
    <nct_id>NCT01906619</nct_id>
  </id_info>
  <brief_title>Respiratory Physiology in Children With Febrile Seizures.</brief_title>
  <official_title>Investigation of the Respiratory Physiology of Children With and Without Febrile Seizures During Febrile Illness.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sana-Klinikum Lichtenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Febrile seizures occur in 2-5% of the population and are typically limited to children&#xD;
      between 3 months and 5 years-of-age. The pathophysiological link between increased body&#xD;
      temperature and increased seizure susceptibility is unsolved in humans. In a mouse model it&#xD;
      has been shown that young animals had a tendency to hyperventilate thereby causing&#xD;
      intra-cerebral hypocapnia / alkalosis and a decrease of their seizure threshold. This effect&#xD;
      was not observed in older animals. Redressing the pCO2 (carbon dioxide partial pressure) by&#xD;
      breathing carbon dioxide enriched air instantly stopped the seizures.&#xD;
&#xD;
      In this study the investigators want to investigate the respiratory physiology in children&#xD;
      with febrile seizures and compare it to children who have fever but did not have febrile&#xD;
      seizures.&#xD;
&#xD;
      The investigators hypothesize that in children with febrile seizures the rising body&#xD;
      temperature triggers a larger increase of respiratory rate (hyperventilation) and subsequent&#xD;
      drop in pCO2 levels.&#xD;
&#xD;
      This study could provide the basic physiological data for an interventional trial to test the&#xD;
      efficacy of carbon dioxide inhalation to interrupt febrile seizures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is the continuous non-invasive monitoring of&#xD;
&#xD;
        -  body temperature&#xD;
&#xD;
        -  respiratory rate&#xD;
&#xD;
        -  transcutaneous pCO2&#xD;
&#xD;
        -  heart rate&#xD;
&#xD;
        -  pulsoxymetric SaO2 (arterial oxygen saturation) during a febrile illness&#xD;
&#xD;
        -  in children without febrile seizures and&#xD;
&#xD;
        -  in children who had suffered a febrile seizure during the actual febrile illness.&#xD;
&#xD;
      Children will be recruited from the emergency units of the Charité University Hospital and a&#xD;
      large Community Hospital, matched according to age, gender and the cause of their febrile&#xD;
      illness and their data will enter final analysis if their body temperature rose at least once&#xD;
      to or above 38.0 degree C and changed more than 1.0 degree C during the observational period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of transcutaneous pCO2 per change of body temperature [mmHg/degree C]</measure>
    <time_frame>First or second night of febrile illness</time_frame>
    <description>The following parameters are continuously monitored in the sleeping child at night during febrile illness: body temperature, respiratory rate, transcutaneous pCO2, heart rate, pulsoxymetric SaO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of respiratory rate per change of body temperature [1/sec * degree C]</measure>
    <time_frame>First or second night of febrile illness</time_frame>
    <description>The following parameters are continuously monitored in the sleeping child at night during febrile illness: body temperature, respiratory rate, transcutaneous pCO2, heart rate, pulsoxymetric SaO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of transcutaneous pCO2 per change of respiratory rate [mmHg * sec]</measure>
    <time_frame>First or second night of febrile illness</time_frame>
    <description>The following parameters are continuously monitored in the sleeping child at night during febrile illness: body temperature, respiratory rate, transcutaneous pCO2, heart rate, pulsoxymetric SaO2</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Febrile Illness in Children</condition>
  <condition>Seizures, Febrile</condition>
  <arm_group>
    <arm_group_label>Febrile illness WITH febrile seizure</arm_group_label>
    <description>The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febrile illness WITHOUT febrile seizure</arm_group_label>
    <description>The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children with febrile illness between 3 months and 5 years of age with a body temperature&#xD;
        of &gt;38.0 during the monitoring period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Febrile illness with body temperature ≥38.0 degree C&#xD;
&#xD;
          -  50% of study population: never had a febrile seizure&#xD;
&#xD;
          -  50% of study population: simple or complex febrile seizure within one day of&#xD;
             investigation&#xD;
&#xD;
          -  Change of body temperature of ≥1.0 degree C during the monitoring period&#xD;
&#xD;
          -  Provision of written informed consent by the parents or guardians of the child&#xD;
&#xD;
          -  Artefact-free simultaneous measurement of respiratory rate, pCO2 (transcutaneous&#xD;
             probe), body temperature (rectal probe), and heart rate during change of body&#xD;
             temperature of ≥1.0 degree C.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of afebrile seizures&#xD;
&#xD;
          -  Past history of neonatal seizures&#xD;
&#xD;
          -  Retarded psychomotor development&#xD;
&#xD;
          -  Chronic respiratory disease&#xD;
&#xD;
          -  Cardiologic disease&#xD;
&#xD;
          -  Severe other organ disease&#xD;
&#xD;
          -  Permanent medication for chronic disorder&#xD;
&#xD;
          -  Therapeutic increase of inspiratory oxygen concentrations during the observational&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schuelke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Schuelke, MD</last_name>
    <phone>+49 30 4505 66468</phone>
    <email>markus.schuelke@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marret Heinold</last_name>
    <phone>+49 30 450 539 720</phone>
    <email>marret.heinold@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schuelke, MD</last_name>
      <phone>+4 9 30 4505 66468</phone>
      <email>markus.schuelke@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Marret Heinold</last_name>
      <phone>+49 30 450 539 720</phone>
      <email>marret.heinold@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Schuelke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Engelke Anne-Sophie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 20, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Markus Schuelke, M.D.</investigator_full_name>
    <investigator_title>Prof. Dr. med. / Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Febrile Seizure</keyword>
  <keyword>Respiratory physiology</keyword>
  <keyword>Respiratory drive</keyword>
  <keyword>Respiratory alkalosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Seizures, Febrile</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

